CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Activity

Progress
1
Course Completed
Activity Information

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: July 21, 2021

Expiration: July 20, 2022